Resistance of hypertensive patients to large doses of guanethidine is seldom due to defective absorption of the drug, since the existence of adrenergic blockade can be demonstrated in these cases.
Vascular sensitivity
Hypotension Myocardial infarction IN A RECENT survey of 224 hypertensive patients treated with guanethidine over a period of 5 years blood pressure control was unsatisfactory (standing diastolic pressure not reduced below 115 mm Hg) in 38 cases (17%). 1 The management of these patients often presents a problem, since it has been our experience that other hypotensive agents such as methyldopa and bethanidine are rarely successful when guanethidine has failed.
Among those effectively treated the range of dosage of guanethidine was from 10 mg to 200 mg daily but in practice increasing the dose beyond 150 mg has seldom seemed to enhance the hypotensive effect. This great variation in drug requirement is difficult to explain. The height of the blood pressure before treatment has not appeared consistently to influence dosage nor is there any difference in this respect in the behavior of patients with primary or secondary hypertension.' Differences in absorption of guanethidine can almost certainly be ruled out. Crushing of the tablets rarely seems to improve response and Leishman and Sandler2 demonstrated the close relationship between oral and parenteral doses of guanethidine. Furthermore, as will be shown later, absorption of the drug can scarcely be at fault since even in refractory cases it has invariably been found that adrenergic blockade is already established. Circulation, Volume XXXVIII, September 1968 Although the mechanism of action of guanethidine is still not fully understood, it is known that the drug can block transmission of nerve impulses along the sympathetic nerves and also leads to depletion of catecholamine from the tissue stores.3 4 However, the main site of production of catecholamines, the adrenal glands, are unaffected by guanethidine so that continuous synthesis and release of endogenous norepinephrine still take place in the guanethidine-treated patient. 5 6 It has been shown both experimentally and in human subjects that administration of guanethidine enhances vascular sensitivity to the effects of norepinephrine7-9 and it has been suggested7' 10, 11 that the development of "tolerance" to drugs such as bretylium and guanethidine may be related to this phenomenon. In the case of tolerance to bretylium, Laurence and NagleI2 found that blood pressure could be effectively reduced by intravenous phentolamine. If the failure to control blood pressure in certain patients despite the administration of an adequately adrenergic-blocking dose of guanethidine was due to the development of increased vascular reactivity, it seemed possible that this also would prove specifically amenable to an adrenolytic agent. This paper describes observations that have led to our successful 
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Figure 2
Valsalva maneuver, on guanethidine.
causing adrenergic blockade. To demonstrate this, use was made of the Valsalva maneuver in which the blood pressure overshoot (with consequent reflex bradycardia) following release of the expiratory strain is dependent on the functional integrity of the sympathetic nervous system.13 If sympathetic transmission is blocked by a drug such as guanethidine, this overshoot of blood pressure and bradycardia does not occur. * Figure 1 shows the heart rate changes during the Valsalva maneuver in a normal subject and figure 2 in a guanethidine-treated patient; it will be seen in the latter that bradyeardia no longer occurs in the third phase of the maneuver. Table 1 compares the heart rate during the Valsalva maneuver in 12 patients with good blood pressure control following guanethidine and 11 patients resistant to guanethidine. The *The patient by blowing raised a sphygmomanometer mercury column to the 60 mm mark and maintained the pressure at this level as long as possible while an electrocardiogram was recorded continuously to record heart rate. The beginning and ending of the expiratory strain were marked on the electrocardiogram, and the heart rate was noted during the initial control period, the period of expiratory strain, and following the release of the strain. two groups are similar in that neither shows a fall in the mean heart rate when the expiratory strain is released, thus indicating that both groups are under successful adrenergic blockade.
Intravenous Phenoxybenzamine
Phenoxybenzamine is a specific inhibitor of norepinephrine on the alpha receptors of the sympathetic nervous system.14 It was assumed therefore that the response to this drug would provide some estimate of the degree of peripheral vasoconstriction induced by endogenous norepinephrine in guanethidine-treated patients, since phenoxybenzamine should reverse any increase in blood pressure resulting from the development of arteriolar hypersensitivity.
Injections of 1 mg of phenoxybenzamine and of a placebo solution were given intravenously on a double-blind basis to 14 hypertensive patients both before and after treatment with guanethidine and the results are shown in table 2. The fall in blood pressure is recorded in millimeters of mercury and as a percentage of the initial diastolic pressure. It will be seen that both before and after treatment with guanethidine the hypotensive effect of phenoxybenzamine is considerably greater than that of the placebo, the chi-square test showing this to be a highly significant difference (P < 0.025). In table 3 the effect of 1 mg of intravenous phenoxybenzamine is shown in 21 hypertensive patients before and after treatment with guanethidine. In this table the patients are divided into two groups, depending on their subsequent response to oral guanethidine, those showing good blood pressure control (standing diastolic pressure below 100 mm Hg) and those with unsatisfactory response (standing diastolic pressure above 100 mm Hg). When given before guanethidine treatment was started, phenoxybenzamine caused a similar mean fall of standing diastolic pressure in both groups, 16% in those who were later well controlled and 15% in those subsequently poorly controlled. After treatment with guanethidine, however, there is a distinct difference between the well controlled and the poorly controlled groups; the blood pressure fall was 15% in the well controlled group, closely similar to the pre-guanethidine response but in the poorly controlled the mean fall in the standing diastolic pressure increased to 25% of the initial diastolic pressure. This result supports the view that in patients not responding adequately to guanethidine the maintenance of high blood pressure is in some measure due to the effect of endogenous norepinephrine whereas when blood pressure control is satisfactory with guanethidine, increased sensitivity of the blood vessels to norepinephrine is not of importance. The Valsalva maneuver was carried out in all patients, both well and poorly controlled, and satisfactory adrenergic blockade was demonstrated in both groups.
Intravenous Infusion of Norepinephrine
In the light of these results it was logical to make direct tests of sensitivity to norepinephrine in representative hypertensive patients. The intravenous infusion of norepinephrine in hypertensive subjects inevitably demanded vigilance and care, but provided the dose employed was appropriately low, it was not regarded as being hazardous. All the patients receiving infusions were volunteers to whom the significance of the procedure was first fully explained. As a precaution, a syringe containing 5 mg of phentolamine was available for immediate intravenous use but was never required. One patient complained of occipital headache, which coincided with rise of blood pressure; otherwise no adverse reactions were encountered.
Infusion of norepinephrine was made by cath-eter into an antecubital vein with a 20 ml disposable syringe, the plunger of which was moved by a Palmer infusion pump. The pump was set to move the syringe plunger 1 inch in 20 minutes, and the solution of norepinephrine was such that 3 /g were injected per minute, the injection being given for 3 minutes. Before starting the pump 5% dextrose was dripped slowly into the vein, and when basal blood pressure readings were obtained, the syringe was attached to the catheter and the infusion of norepinephrine begun. Blood pressure was recorded on the opposite arm at intervals of 1 minute by an observer who was unaware when the pump was switched on and off. Recordings were continued until readings were again consistently basal. The lying diastolic pressure was used as the standard of comparison owing to the difficulty of recording standing blood pressure during intravenous infusions. 
Figure 3
Blood pressure response to norepinephrine infusion in three categories of hypertensive patients. Category I-Three hypertensive patients receiving large doses of guanethidine (> 100 mg daily) with blood pressure poorly controlled (lying diastolic pressure > 110 mm Hg).
Category II-Three hypertensive patients receiving large doses of guanethidine (> 100 mg daily) with blood pressure well controlled (lying diastolic pressure < 100 mm Hg).
Category III-Three untreated hypertensive patients with blood pressure of the same order as in category I. The purpose of this group was to insure that any increase in norepinephrine effect observed in category I was not the result simply of a higher initial blood pressure.
The results are shown in figure 3 . It will be seen that the infusion of norepinephrine at the rate of 3 ,ug per minute consistently caused a rise in diastolic pressure. In two of the three poorly controlled patients (category I) the rise was exceptional and in all three of these the duration of the hypertensive effect was notably longer than in the other two groups. There was little difference in the behavior of the blood pressure in the well-controlled and untreated groups. These observations therefore lend support for the view that resistance of hypertension to guanethidine is associated with increased sensitivity to norepinephrine.
Oral Phenoxybenzamine in the Treatment of Guanethidine-Resistant Hypertension
Following the demonstration that the blood Circtlation, Volume XXXVIII, September 1968 pressure of hypertensive patients resistant to guanethidine is both especially sensitive to norepinephrine and responsive to phenoxybenzamine, this latter drug was given by mouth as additional therapy to 16 hypertensive patients poorly controlled despite large doses of guanethidine. Four cases had failed to show at any time a response to guanethidine, whereas the remaining 12 were refractory on account of acquired tolerance. The starting dose of phenoxybenzamine was 10 mg daily, which was increased if necessary by increments of 10 mg at weekly intervals. Fifteen of these patients have been taking this combination of drug for periods ranging from 3 to 30 months, and the results are shown in table 4. It will be seen that before starting treatment with hypotensive drugs all of these patients had severe hypertension with standing diastolic pressure ranging from 130 to 158 mm Hg. Although some fall of blood pressure had usually been achieved by guanethidine, with or without a diuretic, this was in all cases inadequate. When phenoxybenzamine was added, blood pressure became well controlled (standing diastolic pressure <100 mm Hg) in 10 cases, moderately controlled (standing diastolic pressure 100 to 110 mm Hg) in three cases and remained poorly controlled in two cases. In one further patient phenoxybenzamine was discontinued as the drug appeared to be without effect. Six patients developed some degree of tolerance to phenoxybenzamine but so far this has been fairly readily overcome and only one patient requires as much as 60 mg of the drug daily. In six of 13 cases with controlled blood pressure it was possible to make some reduction in the daily dose of guanethidine, but in the remainder attempts to do this led to loss of blood pressure control. None of the patients taking phenoxybenzamine complained of any side effects.
Treatment of Hypertension with Oral Phenoxybenzamine Alone
In order to determine to what extent the successful management of guanethidine-re- sistant patients with a combination of guanethidine and phenoxybenzamine was due to the hypotensive effect of phenoxybenzamine alone, a double-blind trial of phenoxybenzamine as the sole hypotensive agent was made in 19 hypertensive patients. These included 10 in-patients, nine of whom had a severe degree of hypertension (standing diastolic pressure from 120 to 150 mm Hg) and nine out-patients, with diastolic pressures ranging from 100 to 130 mm Hg. The dose of oral phenoxybenzamine was the maximum dose used in the combined guanethidinephenoxybenzamine regime, namely, 60 mg, which was given in three divided doses. Identical placebo capsules were provided, neither the observer nor the patient being aware which preparation was being used. The in-patients were treated for 3 days with either active drug or placebo, the choice being randomized. Following a day free from treatment the alternative capsules were then given for a further three days, and standing diastolic pressure was recorded daily. Outpatient treatment covered a period of three weeks and patients were given a week's supply of either active drug or placebo based on a previously randomized distribution involving either an ABA or BAB order over the 3-week period. The patients attended weekly, at which time both lying and standing blood pressures were recorded and side effects were noted.
The in-patient results are shown in table 5. The mean standing diastolic pressure was similar before each 3-day period of drug administration, and phenoxybenzamine was consistently more effective in lowering the blood pressure than the placebo on each of the 3 days. However, two of the 10 patients had to stop treatment after the second or third day on phenoxybenzamine, in one case because of myocardial infarction and in the second case owing to severe dizziness consequent upon marked hypotension.
The results in out-patients are shown in table 6 . Four patients received phenoxybenzamine for two separate weeks and five patients received the placebo for the 2 weeks as a result of the random distribution of the "'sandwich" course. It can be seen that phenoxybenzamine was more effective than the placebo in controlling the standing diastolic pressure but the difference was not striking. In addition, six further out-patients had to stop taking the phenoxybenzamine Circulation, Volume XXXVIII, September 1968 during the first week of its administration because of a variety of severe side effects, including dizziness, postural syncope, palpitations, sleepiness, and tiredness.
Discussion
Hypersensitivity of peripheral arterioles to norepinephrine following administration of guanethidine is well recognized7-9 and is similar to the phenomenon observed in surgically sympathectomized limbs. As a result of this, although satisfactory adrenergic blockade can be established by guanethidine the level of blood pressure may be adversely influenced by the vasoconstrictor effect of endogenous circulating norepinephrine; this has evidently been the case in most of the patients we have studied. All the guanethidine-resistant patients showed satisfactory adrenergic blockade during the Valsalva maneuver, and the existence of norepinephrine hypersensitivity has been demonstrated experimentally by intravenous infusion and more indirectly by the hypotensive effect of intravenous administration of the specific norepinephrine inhibitor, phenoxybenzamine. The practical application of this concept has also been shown in the satisfactory blood pressure control of guanethidine-resistant patients with a combination of guanethidine and phenoxybenzamine by mouth for periods as long as 30 months.
The excessive vascular reactivity to norepinephrine shown in the poorly controlled guanethidine-treated patients in the present study can be associated either with increased amounts of circulating norepinephrine or with qualitative alteration in vascular sensitivity to circulating norepinephrine. However, Gitlow and associatesl5 by using tritiated norepinephrine have shown that there is no quantitative increase in circulating norepinephrine or in urinary excretion of norepinephrine and its metabolites as a result of treatment with guanethidine. It therefore seems more likely that the excessive vascular reactivity observed in our patients was due to increased sensitivity to normal amounts of circulating norepinephrine.
Hypersensitivity of tissue receptors to norepinephrine in guanethidine-treated patients may be due to the blocking effect of guanethidine on the mechanism by which released norepinephrine is recaptured by the sympathetic nerves with the result that free active norepinephrine remains at the arteriolar site for prolonged periods, causing sustained vasoconstriction.4 This is in accord with our findings following norepinephrine infusion, since a notable feature of the pressor reaction was the long duration of this response in the guanethidine-treated patients with unsatisfactory blood pressure control as compared with patients who were either well controlled or untreated by guanethidine. Trendelenburg'6 has suggested that pretreatment with guanethidine does not interfere with the uptake of catecholamine but "binding" does not take place in the sympathetic nerve endings, as catecholamine is deaminated by the intraneuronal monoamine oxidase. Similar interference with "binding" of catecholamines is caused by reserpine. It is interesting therefore that Moyer and as-sociates17 showed that the addition of phenoxybenzamine could restore blood pressure control to reserpine-resistant hypertensive patients, also that Pickering and associates'8 commented on the effectiveness of a small dose of phenoxybenzamine when used in combination with reserpine, for this is very similar to our experience with phenoxybenzamine in combination with guanethidine.
Our own observations as well as those of Corcoran and associates'9 and Miller and associates20 have shown that phenoxybenzamine by itself has moderate hypotensive capability but the drug taken alone is clearly unsuitable for the treatment of hypertensive patients on account of both the inconsistency of its hypotensive action and the considerable side effects. The hypotensive effect of phenoxybenzamine alone compares unfavorably with the response seen when the drug is given as additional therapy to patients who have become tolerant to guanethidine. In the latter case not only is the blood pressure more consistently lowered but the patients appear responsive to smaller doses of phenoxybenzamine and side effects, which are troublesome when the drug is given alone, are no longer encountered. These findings have suggested a specific sensitivity to phenoxybenzamine rather than a simple summation of the hypotensive effect of two drugs, and they appear compatible with the hypothesis that failure to control blood pressure by guanethidine is in most cases due to enhanced sensitivity to endogenous norepinephrine.
